Sorbent Therapeutics, a US-based kidney treatment company, has raised $16.8m of a $21.8m series B round from 10 investors, according to a regulatory filing with the Securities and Exchange Commission.
William Rajski, founder and chief financial officer at Sorbent, said the full amount had been raised with $16.8m invested at the end of June and ther remaining $5m "to be received prior to January 15", confirming a report by news provider MedCity, which revealed the filing.
Rajski added: "Sorbent raised $6.5[m] in December of 2005 and $7.8[m] in January of 2007 related to [Sorbent’s] series A. Total of A & B is $36.1[m]."
The SEC filing also showed Sorbent had raised $7.8m of a $10.6m debt round in 2007 and the year before closed its series A round at $19.2m.
The company’s website said its investors are: chemicals company Dow Chemical and venture capital firms Arch Venture Partners, Sofinnova Ventures and CMEA Capital. MedCity said Canada-based VC AgeChem Financial had also joined the consortium.